AR132041A1 - Anticuerpos cd16a y métodos de uso - Google Patents

Anticuerpos cd16a y métodos de uso

Info

Publication number
AR132041A1
AR132041A1 ARP240100529A ARP240100529A AR132041A1 AR 132041 A1 AR132041 A1 AR 132041A1 AR P240100529 A ARP240100529 A AR P240100529A AR P240100529 A ARP240100529 A AR P240100529A AR 132041 A1 AR132041 A1 AR 132041A1
Authority
AR
Argentina
Prior art keywords
antigen
binding fragment
cd16a
antibody
construct
Prior art date
Application number
ARP240100529A
Other languages
English (en)
Inventor
Qiansheng Ren
Liang Qu
Wenjie Wang
Liu Xue
Zhuo Li
Chichi Huang
Original Assignee
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh
Publication of AR132041A1 publication Critical patent/AR132041A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno que se unen específicamente a CD16A humana. Reivindicación 1: Un anticuerpo anti-CD16A o fragmento de unión a antígeno del mismo, que comprende un anticuerpo o fragmento de unión del mismo que se une específicamente a CD16A humana. Reivindicación 13: Un constructo que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes. Reivindicación 18: Una composición farmacéutica que comprende el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo de cualquiera de las reivindicaciones precedentes y un portador farmacéuticamente aceptable. Reivindicación 19: Un ácido nucleico aislado que codifica el anticuerpo anti-CD16A o el fragmento de unión a antígeno del mismo o constructo de cualquiera de las reivindicaciones 1 - 17. Reivindicación 20: Un vector que comprende el ácido nucleico de la reivindicación 19. Reivindicación 21: Una célula huésped que comprende el ácido nucleico de la reivindicación 19 o el vector de la reivindicación 20. Reivindicación 22: Un proceso para producir un anticuerpo anti-CD16A o un fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de la reivindicación 21 y recuperar el anticuerpo o el fragmento de unión a antígeno o el constructo a partir del cultivo.
ARP240100529A 2023-03-03 2024-03-01 Anticuerpos cd16a y métodos de uso AR132041A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023079509 2023-03-03

Publications (1)

Publication Number Publication Date
AR132041A1 true AR132041A1 (es) 2025-05-21

Family

ID=90544635

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100529A AR132041A1 (es) 2023-03-03 2024-03-01 Anticuerpos cd16a y métodos de uso

Country Status (7)

Country Link
US (1) US20260008853A1 (es)
EP (1) EP4676965A1 (es)
JP (1) JP2026506241A (es)
CN (1) CN120813603A (es)
AR (1) AR132041A1 (es)
TW (1) TW202436344A (es)
WO (1) WO2024183636A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121758624A (zh) * 2024-09-23 2026-03-31 北京智仁美博生物科技有限公司 结合人cd16和/或人cd123的多种抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
DK3107938T3 (da) 2014-05-28 2022-07-11 Zymeworks Inc Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
CN108283001B (zh) 2015-10-08 2022-08-19 酵活有限公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
US20240101677A1 (en) * 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
JP2024524378A (ja) * 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Cd16抗体及びその応用
US20240352128A1 (en) * 2021-08-25 2024-10-24 Nanjing GenScript Biotech Co., Ltd. ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a

Also Published As

Publication number Publication date
JP2026506241A (ja) 2026-02-20
CN120813603A (zh) 2025-10-17
WO2024183636A1 (en) 2024-09-12
TW202436344A (zh) 2024-09-16
US20260008853A1 (en) 2026-01-08
EP4676965A1 (en) 2026-01-14

Similar Documents

Publication Publication Date Title
MX2024006968A (es) Anticuerpos cdh17 y metodos de tratamiento del cancer.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
RU2013111533A (ru) Способы получения мультиспецифичных и мультивалентных антител
BR112023020371A2 (pt) Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO
SA522440646B1 (ar) أجسام مضادة ترتبط بـ siglec15 واستخداماتها
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
MX2022014243A (es) Proteina de union al antigeno st2.
AR125074A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR131527A1 (es) Anticuerpos anti-b7h3 y métodos de uso
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso
AR132159A1 (es) Anticuerpos anti-b7h3 y métodos de uso
PE20251175A1 (es) Anticuerpos anti-bmp9 y metodos de uso de los mismos
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR130641A1 (es) Anticuerpos anti-cd28
AR130129A1 (es) Constructos de unión a cd98 para tratar tumores cerebrales
MX2024006969A (es) Anticuerpos dlk1 y metodos de tratamiento del cancer.
AR127445A1 (es) Anticuerpos de unión a claudina 18.2 y fragmentos de estos